Inactive Instrument

Ibex Technologies

Equities

IBT

CA4489375085

Delayed Toronto S.E. Other stock markets 01:13:49 2024-04-05 pm EDT			5-day change	1st Jan Change
1.44 ^CAD	-.--%		-.--%	+21.01%

Apr. 08	IBEX Completes C$37.9-Million Sale Of the Company	MT
Apr. 08	BBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. from Milfam LLC, McLean Capital Inc., Paul Baehr and others.	CI

IBEX Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024

March 22, 2024 at 04:54 pm EDT

IBEX Technologies Inc. reported earnings results for the second quarter and six months ended January 31, 2024. For the second quarter, the company reported sales was CAD 1.92 million compared to CAD 1.72 million a year ago. Net income was CAD 0.049664 million compared to CAD 0.100033 million a year ago.
For the six months, sales was CAD 3.98 million compared to CAD 3.47 million a year ago. Net income was CAD 0.859943 million compared to CAD 0.77854 million a year ago. Basic earnings per share from continuing operations was CAD 0.03 compared to CAD 0.03 a year ago.

Latest news about Ibex Technologies

IBEX Completes C$37.9-Million Sale Of the Company	Apr. 08	MT
BBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. from Milfam LLC, McLean Capital Inc., Paul Baehr and others.	Apr. 07	CI
IBEX Shareholders Approve the C$37.9-Million Sale of Company	Apr. 03	MT
Refile: IBEX Reports Results For The Second Quarter And Six Months Ending Jan. 31, 2024	Mar. 25	MT
IBEX Reports Results For The Second Quarter And Six Months Ending Jan. 31, 2024	Mar. 25	MT
IBEX Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 22	CI
IBEX Reports Results For The Second Quarter And Six Months Ending January 31, 2024	Mar. 22	MT
IBEX Technologies Issues Management Circular Ahead of Vote of C$37.9-Million Acquisition Offer	Feb. 23	MT
IBEX Technologies Signs Definitive Agreement to Sell Company for $1.45 Cash Per Share	Feb. 12	MT
15720273 Canada Inc. entered into a binding acquisition agreement to acquire IBEX Technologies Inc. from Milfam LLC, McLean Capital Inc., Paul Baehr and others for CAD 35.5 million.	Feb. 11	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022.	Dec. 14	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on July 17, 2023.	Dec. 14	CI
IBEX Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 14	CI
IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024	Dec. 14	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022.	Nov. 09	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on July 17, 2023.	Nov. 09	CI
IBEX Technologies Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	Nov. 09	CI
IBEX Technologies Inc.'s Equity Buyback announced on August 2, 2022, has expired with 64,600 shares, representing 0.26% for CAD 0.04 million.	23-08-03	CI
IBEX Technologies Renews Normal Course Issuer Bid	23-07-17	MT
IBEX Technologies Inc. announces an Equity Buyback for 1,500,000 shares, representing 6.06% of its issued share capital.	23-07-17	CI
IBEX Technologies Inc. authorizes a Buyback Plan.	23-07-16	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022.	23-06-07	CI
IBEX Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-07	CI
IBEX Technologies Fiscal Q2 Profit Falls 75% on Weaker Sales	23-03-20	MT
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022.	23-03-20	CI

Chart Ibex Technologies

Duration

Period

More charts

Company Profile

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.âs primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISAâs) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.

Sector

More about the company